Pulmonary Arterial Hypertension Market Size to Surpass USD 13.5 Billion by 2028

The latest research study released by Transparency Market Research on "Pulmonary Arterial Hypertension (PAH) Market Forecast to 2023-2028 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Pulmonary Arterial Hypertension (PAH) industry, as well as predicted future growth, technological advancements, investment prospects, market economics, and financial data.

The global Pulmonary Arterial Hypertension (PAH) market, valued at US$ 5.2 billion in 2020, is projected to witness significant expansion, with an estimated Compound Annual Growth Rate (CAGR) of 5.4% from 2021 to 2028. The market is anticipated to reach a valuation of US$ 13.5 billion by the end of 2028, according to the latest report by Transparency Market Research

Get a Sample Copy of the Pulmonary Arterial Hypertension (PAH) Market Research Report (Use Corporate Mail Id for Quick Response) -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

"Connect with our team of research specialists and unlock the optimal solution for driving your business growth"

Market Dynamics and Trends

Research and development in drug discovery platforms, collaborative efforts by healthcare professionals, and government initiatives to introduce new drugs are key drivers of the global PAH market, even amid the challenges posed by the coronavirus pandemic. Companies in the market are actively accelerating product development, leveraging revenue opportunities, and extending services to gain a competitive edge. However, a lack of awareness about PAH treatment and detection is expected to hamper market growth during the forecast period.

Increase in Awareness about Pulmonary Arterial Hypertension

PAH, a rare and progressive disorder characterized by high blood pressure in pulmonary arteries, has seen an uptick in prevalence due to risk factors such as HIV, sedentary lifestyles, tobacco and alcohol consumption, smoking, and other idiopathic conditions. Market players have opportunities for growth due to the increasing prevalence of PAH globally. Various treatments are available in the market to control and slow down the disease's progression, improving the quality of life for patients. Favorable government policies and approvals of effective drugs contribute to the demand in the global PAH market.

Inquire more about this report before purchase - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1181

Rapid Growth in Geriatric Population to Fuel Market Expansion

The rise in the geriatric population in developing countries is expected to drive the global PAH market. The increasing incidence of PAH in the elderly, coupled with awareness programs, is boosting market growth. Aging, a non-modifiable risk factor, increases susceptibility to PAH. Educational initiatives are underway to increase awareness about PAH among healthcare providers and patients.

Technological Advancements and Approval of New Drugs to Drive Global Market

Technological advancements in drug discovery and development, coupled with research and development activities, are driving the PAH market. The market is classified based on drug class into prostacyclin & prostacyclin analogs, PDE-5 inhibitors, ERAs (endothelin receptor antagonists), and soluble guanylate cyclase (sGC) stimulators. The prostacyclin & prostacyclin analogs segment is expected to dominate, while the sGC stimulators segment is anticipated to grow rapidly. The approval of new drugs and a promising drug pipeline contribute to market growth

Competitor Analysis:

The significant players operating in the global Pulmonary Arterial Hypertension (PAH) market are

Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Pfizer, Inc., and United Therapeutics Corporation

Market Segmentation -

Drug Class

Prostacyclin & Prostacyclin Analogs
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
 Pipeline Analysis

Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
This Report lets you identify the opportunities in Pulmonary Arterial Hypertension (PAH) Market by means of a region:

North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

Have Any Query? Ask To Analyst: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=1181

Key Features of the Pulmonary Arterial Hypertension (PAH) Market Report: -

➤ Analyze competitive developments such as expansions, deployments, new product launches, and market acquisitions.

➤ Examine the market opportunities for stakeholders by identifying higher growth sections.

➤ To study and analyze the global Pulmonary Arterial Hypertension (PAH) industry status and forecast including key regions.

➤ An in-depth analysis of key product segments and application spectrum, providing strategic recommendations to incumbents and new entrants to give them a competitive advantage over others.

➤ It provides a comprehensive analysis of key regions of the industry as well as a SWOT analysis and Porter's Five Forces analysis to provide a deeper understanding of the market.

➤ It helps you make strategic business decisions and investment plans.

Research Methodology

The report has its roots definitely set in thorough strategies provided by proficient data analysts. The research methodology involves the collection of information by analysts only to have them studied and filtered thoroughly in an attempt to provide significant predictions about the market over the review period. The research process further includes interviews with leading market influencers, which makes the primary research relevant and practical. The secondary method gives a direct peek into the demand and supply connection. The market methodologies adopted in the report offer precise data analysis and provide a tour of the entire market. Both primary and secondary approaches to data collection have been used. In addition to these, publicly available sources such as annual reports, and white papers have been used by data analysts for an insightful understanding of the market.

Reasons to Buy The Pulmonary Arterial Hypertension (PAH) Market Report: -

1.Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.

2.Reports provide opportunities and threats faced by suppliers in the Pulmonary Arterial Hypertension (PAH) industry around the world.

The report shows regions and sectors with the fastest growth potential.

3.A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.

4.The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.

5.This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.

More Trending Reports by Transparency Market Research -

Cold Plasma Market

https://www.globenewswire.com/en/news-release/2023/03/30/2638299/0/en/Cold-Plasma-Market-Size-to-Cross-USD-17-3-Bn-by-2032-with-CAGR-of-19-3-Exclusive-Study-by-TMR.html

MicroRNA Market

https://www.globenewswire.com/en/news-release/2023/03/30/2638271/0/en/MicroRNA-Market-Size-to-Reach-USD-15-5-Bn-by-2033-TMR-Study.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us

Nikhil Sawlani

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

This release was published on openPR.